Osel Inc. and March of Dimes Launch Phase 2b Trial for Preterm Birth Prevention Therapy
Osel Inc., in collaboration with the March of Dimes and Imperial College London, has announced the launch of a Phase 2b clinical trial to evaluate LACTIN-V, a microbiome-based therapy aimed at preventing preterm birth. The trial, known as FLIP-2, will assess the efficacy and safety of LACTIN-V in pregnant women at high risk of preterm birth. LACTIN-V contains Lactobacillus crispatus, a beneficial bacterium designed to restore a healthy vaginal microbiome, which is believed to be a significant factor in preventing preterm birth. The trial will enroll 360 participants across four maternity units in the UK. 
